Protagonist Therapeutics, INC

Protagonist Therapeutics announced robust second quarter 2026 financial results, highlighting the successful commercial launch of ICOTYDE, priority review for rusfertide, and significant progress across its internal R&D pipeline.

Protagonist Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved the adoption of the 2026 Equity Incentive Plan, replacing the 2016 plan.

Protagonist Therapeutics announced strong Q1 2026 results, highlighted by the FDA approval of ICOTYDE, a $50 million milestone payment, and significant advancements in its rusfertide and wholly-owned pipeline programs.

Protagonist Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting significant pipeline advancements including two NDA submissions and an extended cash runway.

Protagonist Therapeutics, Inc. provides an updated corporate presentation detailing progress on its lead drug candidates, Icotrokinra and Rusfertide, including recent NDA submissions and a robust R&D pipeline.

Protagonist Therapeutics reported its third quarter 2025 financial results, highlighting significant progress in its icotrokinra and rusfertide programs, alongside pipeline expansion.

Protagonist Therapeutics, Inc. announced substantial revenue growth and a strong cash position in its Q2 2026 10-Q filing, driven by key collaboration milestones.

Protagonist Therapeutics announced strong Q1 2026 results driven by the FDA approval of ICOTYDE, with significant revenue growth and a positive net income.

Protagonist Therapeutics reported a net loss of $39.3 million for Q3 2025, driven by increased R&D spending on new drug candidates, while advancing its Phase 3 programs for icotrokinra and rusfertide.

Protagonist Therapeutics submitted an NDA for icotrokinra and reported positive Phase 3 results for rusfertide, despite a net loss for the quarter due to lower collaboration revenue.

Protagonist Therapeutics' Q1 2025 results show a net loss of $11.655 million, but are highlighted by $28.321 million in license and collaboration revenue, primarily from the Takeda agreement.

Protagonist Therapeutics reports a robust cash position of $583.3 million, driven by a $300 million upfront payment from Takeda, while advancing its clinical programs for rusfertide and JNJ-2113.

Protagonist Therapeutics submitted NDAs for Icotyde and rusfertide in 2025, expanded its pipeline, and ended the year with $646 million in cash despite a net loss.

Protagonist Therapeutics highlights positive Phase 3 results for Icotrokinra, a worldwide license and collaboration agreement for Rusfertide with Takeda, and a strong cash position at the end of 2024.

Protagonist Therapeutics' 2023 10-K filing highlights the progress of their lead drug candidates, rusfertide for blood disorders and JNJ-2113 for inflammatory diseases, along with a new collaboration with Takeda.

Dinesh V Ph D Patel, President and CEO and a Director of Protagonist Therapeutics, Inc, sold 100,000 shares of common stock on August 10, 2026.

Protagonist Therapeutics Director William D. Waddill reported transactions involving the sale of common stock and the exercise of stock options, executed under a pre-arranged 10b5-1 trading plan.

Protagonist Therapeutics director William D. Waddill exercised stock options and sold 9,000 shares under a 10b5-1 trading plan.

Director William D. Waddill exercised options and sold 9,000 shares of Protagonist Therapeutics, Inc. under a 10b5-1 plan.

CEO Dinesh V. Patel exercised 75,000 stock options and sold the resulting shares under a pre-established 10b5-1 trading plan.

Protagonist Therapeutics CEO Dinesh V. Patel exercised 75,000 stock options and sold the resulting shares on May 12, 2026.

Protagonist Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing director elections, executive compensation, and equity plan proposals.

Protagonist Therapeutics has scheduled its 2025 Annual Meeting of Stockholders for June 20, 2025, outlining key voting items for shareholders.

Protagonist Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 20, 2025, covering director elections, executive compensation, and auditor ratification.

Protagonist Therapeutics will hold its annual meeting on June 20, 2024, with proposals including the election of directors, executive compensation, ratification of Ernst & Young LLP as auditor, and an increase in authorized common stock.

Protagonist Therapeutics is holding its annual meeting on June 20, 2024, to vote on director elections, executive compensation, auditor ratification, and an increase in authorized common stock.

Farallon Capital Management, L.L.C. and associated entities have reported a beneficial ownership of 9.99% in Protagonist Therapeutics, Inc. as of June 30, 2026.

State Street Corporation has filed a Schedule 13G, reporting beneficial ownership of 5.2% of Protagonist Therapeutics Inc. common stock as of June 30, 2026.

State Street Corporation has reported beneficial ownership of 4.9% of Protagonist Therapeutics Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.09% of Protagonist Therapeutics Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.53% of Protagonist Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in Protagonist Therapeutics Inc. following an internal realignment.